It was reported that HR deficiency assays, such as detecting nuclear RAD51 foci in tumor cells, could identify patients with BRCA pathogenic variants that are more likely to respond to platinum-containing therapy and PARP inhibitors (37–40). Here, RAD51 is linked to neoplasm.